A call for action: Closing the evidence gap in management of stimulant‐induced psychosis
Addiction · 2026-09 · 121 (9) · 2275-2283
DOI: 10.1111/add.70393 ↗At a glance
Journal article in Addiction, published online on 2026-03-15. Written by Anne Bouthillier and 3 co-authors. Institution: Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada. Major MEDLINE topics: Central Nervous System Stimulants, Psychoses, Substance-Induced. Cited 6 times so far (Crossref); 75 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: CHUM Foundation.
Abstract (original language)
Background
Stimulant‐induced psychosis (StIP) is emerging as one of most pressing health challenges. Over the past two decades, stimulant‐related harms and psychiatric care demands have risen sharply. Individuals with StIP often present with severe agitation and high suicide risk, and up to half progress to chronic psychotic illness within two years. Despite this burden, clinical recommendations remain sparse and largely based on consensus rather than evidence. This article aims to critically appraise current conceptual and therapeutic approaches to StIP, highlight evidence gaps, and outline priorities for research and clinical practice. Argument We propose a re‐evaluation of StIP nosology, shifting away from DSM‐5 distinctions that require symptom presence beyond abstinence and often fail in real‐world settings. Management might require stage‐specific approaches— acute (safety and short‐term antipsychotics), subacute (stabilization and relapse prevention), and long‐term (management of recurrent or persistent psychosis)— yet no validated staging models exist. Antipsychotic prescribing remains guided by expert opinion, with unresolved questions around choice of agent, treatment duration, and relapse prevention strategies. Evidence for psychosocial and behavioral interventions is very limited. Individualized care, supported by predictive tools, biomarkers, and longitudinal risk stratification, is essential to identify individuals at highest risk of progression and chronicity while minimizing unnecessary long‐term pharmacotherapy.
Conclusions
Stimulant‐induced psychosis (StIP) exemplifies a widening evidence‐practice gap. Addressing this requires a coordinated research agenda to address nosology and phenomenology, validate diagnostic algorithms, develop stage‐specific management models, and test integrated pharmacological and behavioral strategies. Without such efforts, outcomes will remain poor, and StIP will continue to represent one of psychiatry's most consequential yet neglected syndromes.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada.
- Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.
- Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
ORCID profiles: Didier Jutras-Aswad
Funding
- CHUM Foundation
Cite
APA
Bouthillier, A., Sharafi, H., Bisaga, A., & Jutras-Aswad, D. (2026). A call for action: Closing the evidence gap in management of stimulant‐induced psychosis. Addiction, 121(9), 2275-2283. https://doi.org/10.1111/add.70393
Vancouver
Bouthillier A, Sharafi H, Bisaga A, Jutras-Aswad D. A call for action: Closing the evidence gap in management of stimulant‐induced psychosis. Addiction. 2026;121(9):2275-2283. doi:10.1111/add.70393
BibTeX
@article{Bouthillier2026,
author = {Bouthillier, Anne and Sharafi, Heidar and Bisaga, Adam and Jutras-Aswad, Didier},
title = {A call for action: Closing the evidence gap in management of stimulant‐induced psychosis},
journal = {Addiction},
year = {2026},
volume = {121},
number = {9},
pages = {2275--2283},
doi = {10.1111/add.70393}
}
EUVIMED